Table 2. Proportion of patients remaining persistent to therapy (90-day definition) at each time point.
| Months since index date | Proportion persistent to therapy, % (p-value vs. DUT-TAM FDC) | ||||||
|---|---|---|---|---|---|---|---|
| DUT-TAM FDC | AB/5ARI free-combination therapy | Finasteride + tamsulosin | Finasteride + alfuzosin | Finasteride + terazosin | Finasteride + doxazosin | Finasteride + silodosin | |
| 6 | 58.7 | 60.8 (p < 0.0001) |
61.2 (p < 0.0001) |
59.7 (p = 0.1502) |
59.8 (p = 0.4797) |
61.3 (p = 0.1933) |
52.4 (p < 0.0001) |
| 12 | 41.8 | 41.0 (p < 0.0001) |
41.4 (p = 0.0768) |
39.4 (p < 0.0001) |
40.1 (p = 0.2755) |
44.0 (p = 0.2718) |
34.0 (p < 0.0001) |
| 18 | 33.4 | 32.3 (p < 0.0001) |
32.7 (p = 0.0012) |
29.9 (p < 0.0001) |
33.4 (p = 1.0000) |
35.4 (p = 0.2961) |
25.3 (p < 0.0001) |
| 24 | 28.2 | 27.1 (p < 0.0001) |
27.5 (p = 0.0007) |
24.5 (p < 0.0001) |
29.9 (p = 0.2320) |
29.9 (p = 0.3520) |
21.3 (p < 0.0001) |
| 36 | 21.3 | 21.0 (p = 0.0840) |
21.4 (p = 0.5941) |
18.6 (p < 0.0001) |
22.8 (p = 0.2464) |
23.8 (p = 0.1325) |
16.0 (p < 0.0001) |
| 48 | 16.6 | 17.0 (p = 0.0112) |
17.3 (p < 0.0001) |
14.9 (p = 0.0012) |
19.2 (p = 0.0270) |
18.6 (p = 0.1854) |
12.5 (p < 0.0001) |
5ARI = 5-α reductase inhibitor; AB = α-blocker; DUT-TAM = dutasteride-tamsulosin; FDC = fixed-dose combination.